[
    [
        {
            "time": "2018-07-26",
            "original_text": "Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2",
            "features": {
                "keywords": [
                    "Earnings Miss",
                    "Revenues Beat",
                    "Q2"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-07-27",
            "original_text": "Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss",
            "features": {
                "keywords": [
                    "Earnings Surpass",
                    "Sales Miss",
                    "Q2"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "scores": {
                "News_content": "Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-11-16",
            "original_text": "November 16th Options Now Available For Eli Lilly",
            "features": {
                "keywords": [
                    "Options Available",
                    "Eli Lilly"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "November 16th Options Now Available For Eli Lilly",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-11-17",
            "original_text": "See what the IHS Markit Score report has to say about Eli Lilly And Co.",
            "features": {
                "keywords": [
                    "IHS Markit Score",
                    "Eli Lilly"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "See what the IHS Markit Score report has to say about Eli Lilly And Co.",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-11-18",
            "original_text": "What Analysts Recommend for Celgene Stock",
            "features": {
                "keywords": [
                    "Analysts Recommend",
                    "Celgene Stock"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "What Analysts Recommend for Celgene Stock",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]